HBV Coinfection
7
1
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Towards a Functional Cure for HBV - The COMMIT Cohort Study
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Prevalence of Occult HBV Infection Among Anti-HBc Alone Group in Northern Taiwan
Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients